(Q44373949)

2 December 2017

title

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. (English)

1 reference

2 December 2017

0 references

3

George Q Daley

1 reference

2 December 2017

Mohammad Azam

1

1 reference

2 December 2017

Robert R Latek

series ordinal

2

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

2 December 2017

1 reference

2 December 2017

volume

112

1 reference

2 December 2017

issue

6

1 reference

2 December 2017

page(s)

831-843

1 reference

An intramolecular SH3-domain interaction regulates c-Abl activity

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Mutational investigation of the specificity determining region of the Src SH2 domain

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

3BP-1, an SH3 domain binding protein, has GAP activity for Rac and inhibits growth factor-induced membrane ruffling in fibroblasts.

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

The role of the linker between the SH2 domain and catalytic domain in the regulation and function of Src.

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Leucine 255 of Src couples intramolecular interactions to inhibition of catalysis

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Crosstalk between the catalytic and regulatory domains allows bidirectional regulation of Src.

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

A myristoyl/phosphotyrosine switch regulates c-Abl

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

The conformational plasticity of protein kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Novel retroviral vectors to facilitate expression screens in mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Structural basis for the autoinhibition of c-Abl tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Intramolecular interactions of the regulatory domains of the Bcr-Abl kinase reveal a novel control mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

In vitro evolution of recognition specificity mediated by SH3 domains reveals target recognition rules

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Autoinhibition of c-Abl

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Smart drugs: tyrosine kinase inhibitors in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Three-dimensional structure of the tyrosine kinase c-Src

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Crystal structures of c-Src reveal features of its autoinhibitory mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS0092-8674%2803%2900190-9

7 January 2021

10.1016/S0092-8674(03)00190-9

Identifiers

DOI

1 reference

2 December 2017

1 reference